Global Payments Leader, Credorax, Rebrands As ‘Finaro’
1.12.2021 19:03:00 EET | Business Wire | Press release
Leading smart payments provider and merchant acquiring bank, Credorax, has today announced its new company identity, Finaro .
Focusing on its core pillars of creating multi-dimensional solutions to simplify payments and going the extra mile for its merchants, Finaro empowers global commerce by providing the ideal solution for cross-border businesses with its cutting-edge technology and superior support.
The news of the rebranding bookends a strong 2021, with Finaro’s impressive 40% Year-on-Year Compound Annual Growth Rate. Founded in 2009, the company currently employs over 350 people, and is based in Israel and Malta, with presence in China Mainland, Hong Kong, the United States and across Europe.
Credorax has already been proven as a payments provider that facilitates its merchants’ growth and with the global fintech industry expected to skyrocket to $190bn by 2026, this rapidly accelerating trajectory creates the perfect environment for Finaro’s new brand to establish itself as a strong player amongst its peers. This huge growth in fintech has seen cross-border sales take more than a quarter of the entire ecommerce marketplace in Europe, highlighting the significance of a provider that can make multidimensional payments brilliantly simple.
Finaro serves over 5000 merchants around the world and in a wide variety of industries, including retail, digital goods and services, travel, hospitality, and mobility. Kiwi.com, Air Baltic, Wolt, Payrexx, Revolut, Go2Mobile and Hero Gaming are among its customers and across all verticals the trend is similar: all merchants are operating within very competitive markets and they are required to create perfect customer experiences. Led by a team of payments experts and solution-creators, Finaro is committed to absorbing the immense complexity of payments and delivering simplicity, so merchants are free to pursue their ambition, knowing they are covered.
“Our company success has always been built on our in-house, cutting-edge full stack platform as well as strong customer relationships, and constant product innovation. Our passionate team of solutions-creators with a can-do approach enable us to create brilliantly simple payment solutions for our merchants, said Igal Rotem, Chief Executive Officer for Finaro.
“Our evolution from Credorax to Finaro reflects the revolution our business has undertaken since joining the payments world 15 years ago and our rebranding is the next step in our growth as a company and on our path towards realizing our vision of commerce, untethered. I’m incredibly proud reveal our new brand identity as Finaro,” Igal continued.
“We came into this industry with a fresh view because we saw obstacles that needed getting beyond, and that’s what we have been doing ever since,” commented Moshe Selfin, Chief Operating & Chief Technology Officer for Finaro. “We pioneered a multidimensional approach to payments that untangles even the most wicked problems in the payments space, paving the way for new and exciting possibilities and giving our merchants a meaningful competitive advantage.”
“Branding is much more than just colours, logos and slogans - it’s about the essence of our company and how we are presented to the world externally. When developing our new brand Finaro, we crystalized our essence, and it was critical to establish our identity as a company that cares about its customers and can deliver the outstanding,” explains Achiya Fried, Chief Commercial Officer of Finaro, “We go the extra mile in flexibility and we co-create solutions with our clients, by providing cutting edge, multidimensional payments solutions, that untangle the complexity of payments. Our new brand, Finaro, reflects just that."
###ENDS###
About Finaro
Finaro is a global cross-border payment provider empowering international commerce through brilliantly simple payments. Our passionate team, exceptional tech capabilities, product innovation, and customer-centric approach enables us to simplify complexity and create multidimensional solutions that generate growth and enable peace of mind for our merchants. To learn more, visit www.finaro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005805/en/
Contact information
Jenna Walker
jenna@skyparlour.com
07591 382 856
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
